About
Breakpoint Therapeutics GmbH is a biotechnology company focused on discovering and developing small-molecule cancer therapies that target DNA damage response pathways, including preclinical polymerase theta (POLQ) inhibitors for oncology indications.
Explore Breakpoint Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.